Gemzar (GEM) + Mitimycin C (MMC) in patients with advanced pancreatic cancer (APC)

Bazin, I.; Garin, A.; Bulat, J.; Нариманов, М. Н.; Nosov, D.; Титов, Д.А.; Попов, А. Ю.; Насырова, Р. Ю.; Tjulandin, S.

doi:10.1016/s0959-8049(99)80984-8

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many other gemcitabine combination studies have been published. [62][63][64][65][66][67][68][69][70][71][72][73][74][75][76][77][78][79] For example, studies with combinations with taxotere, oxaliplatin, epirubicin, mitomycin C, octreotide, tamoxifen, marimastat, capecitabine, and irinotecan, as well as multidrug regimens (epirubicin, cisplatin, and 5-FU), have been conducted. Some of these studies have had encouraging results.…”

Section: Gemcitabine and Other Oncolytic Agentsmentioning

confidence: 99%

What's new in pancreatic cancer treatment?

Fung

Sakata

2002

Journal of Hepato-Biliary-Pancreatic Surgery

View full text Add to dashboard Cite

Pancreatic cancer represents a major challenge to oncologists because of its high chemoresistant nature and dismal outcomes. Conventional therapy for advanced disease relied for a long time on palliative 5-fluorouracil (5-FU)-based chemotherapy, but with unsatisfactory results. The introduction of the novel antimetabolite gemcitabine provides new optimism for patients with advanced pancreatic cancer, as multiple clinical trials have demonstrated the superiority of gemcitabine over 5-FU and other agents for these patients. The benefits of gemcitabine over conventional therapies include improved response rate and enhanced survival, as well as improvement in disease-related symptoms and quality of life in these patients. With these data, gemcitabine is widely accepted worldwide as the therapy of choice by many oncologists for advanced pancreatic cancer. The current review presents an overview of the clinical studies of gemcitabine over the past decade for the treatment of patients with advanced pancreatic cancer. Other investigational regimens or uses (e.g., fixed dose-rate infusion, intraarterial infusion, adjuvant use, chemo-radiation, etc) are also reviewed.

show abstract

Section: Gemcitabine and Other Oncolytic Agentsmentioning

confidence: 99%

What's new in pancreatic cancer treatment?

Fung

Sakata

2002

Journal of Hepato-Biliary-Pancreatic Surgery

View full text Add to dashboard Cite

show abstract

The role of gemcitabine alone and in combination in the treatment of pancreatic cancer

et al. 2000

View full text Add to dashboard Cite

Pancreatic cancer, one of the most frequently reported gastrointestinal tumors, has a 5-year survival of less than 5%. Despite representing only 2-3% of the total cancer incidence, it is the fifth leading cause of cancer death. This is because it is commonly only diagnosed at an advanced stage. Until recently the traditional therapy for patients with advanced disease was palliative 5-fluorouracil (5-FU)-based chemotherapy. However, the novel antinucleoside gemcitabine (Gemzar) has demonstrated a survival benefit over 5-FU, and an improvement in disease-related symptoms and quality of life in patients with advanced disease. This review presents an overview of the clinical studies of gemcitabine, either alone or in combination, with other chemotherapeutic agents and/or radiation therapy, in the treatment of these patients. A comparison of these studies is made with those using alternative treatment regimens. The data suggest that gemcitabine in combination with biomodulated 5-FU should be considered the standard palliative treatment to which other new drug combinations or combined modality chemoradiation regimens should be compared.

show abstract

Gemzar (GEM) + Mitimycin C (MMC) in patients with advanced pancreatic cancer (APC)

Cited by 2 publications

References 0 publications

What's new in pancreatic cancer treatment?

What's new in pancreatic cancer treatment?

The role of gemcitabine alone and in combination in the treatment of pancreatic cancer

Contact Info

Product

Resources

About